Table 2.
Risk of cardiovascular events after primary Sjögren's syndrome diagnosis in an inception cohort of 960 primary Sjögren's syndrome patients and 9035 matched comparators from the general population
| Event | SSA/SSB antibody status | No. events (%) | Person‐years | Incidence rate per 1000 person‐years (95% CI) | Risk estimate | Median time to eventa, years | Excluded individuals due to prior event, n | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pSSb | Controlsc | pSS | Controls | pSS | Controls | Hazard ratio | 95% CI | pSS | Controls | pSS | Controls | ||
| Myocardial infarction | All | 53 (5.6%) | 333 (3.7%) | 9450 | 91 958 | 5.6 (4.3–7.3) | 3.6 (3.3–4.0) | 1.6 | 1.2–2.1 | 8.9 | 8.5 | 12 | 110 |
| SSA/SSB DPd | 16 (4.1%) | 113 (3.1%) | 4152 | 40 183 | 3.9 (2.4–6.3) | 2.8 (2.3–3.4) | 1.4 | 0.8–2.4 | 11.7 | 8.7 | 3 | 32 | |
| SSA/SSB SPe | 17 (6.2%) | 86 (3.4%) | 2546 | 24 886 | 6.7 (4.2–10.7) | 3.5 (2.8–4.3) | 2.0 | 1.2–3.4 | 7.1 | 8.5 | 6 | 43 | |
| SSA/SSB neg.f | 19 (7.0%) | 123 (4.8%) | 2625 | 25 519 | 7.2 (4.6–11.3) | 4.8 (4.0–5.8) | 1.5 | 0.9–2.5 | 10.3 | 7.9 | 3 | 32 | |
| Cerebral infarction | All | 34 (3.6%) | 278 (3.1%) | 9497 | 92 615 | 3.6 (2.6–5.0) | 3.0 (2.7–3.4) | 1.2 | 0.9–1.7 | 11.3 | 8.7 | 5 | 85 |
| SSA/SSB DP | 18 (4.6%) | 104 (2.8%) | 4089 | 40 252 | 4.4 (2.8–7.0) | 2.6 (2.1–3.1) | 1.7 | 1.0–2.9 | 13.6 | 8.1 | 1 | 25 | |
| SSA/SSB SP | 7 (2.5%) | 84 (3.3%) | 2601 | 25 129 | 2.7 (1.3–5.6) | 3.3 (2.7–4.1) | 0.8 | 0.4–1.8 | 13.1 | 8.5 | 3 | 30 | |
| SSA/SSB neg. | 8 (2.9%) | 85 (3.3%) | 2675 | 25 803 | 3.0 (1.5–6.0) | 3.3 (2.7–4.1) | 0.9 | 0.4–1.9 | 9.0 | 9.7 | 1 | 29 | |
| Venous thromboembolism | All | 50 (5.3%) | 238 (2.7%) | 9282 | 92 300 | 5.4 (4.1–7.1) | 2.6 (2.3–2.9) | 2.1 | 1.6–2.9 | 7.7 | 8.5 | 25 | 126 |
| SSA/SSB DP | 24 (6.3%) | 80 (2.2%) | 3976 | 40 262 | 6.0 (4.0–9.0) | 2.0 (1.6–2.5) | 3.1 | 1.9–4.8 | 5.1 | 10.4 | 9 | 45 | |
| SSA/SSB SP | 13 (4.8%) | 76 (3.0%) | 2580 | 25 006 | 5.0 (2.9–8.7) | 3.0 (2.4–3.8) | 1.7 | 0.9–3.0 | 9.7 | 7.9 | 7 | 35 | |
| SSA/SSB neg. | 12 (4.5%) | 74 (2.9%) | 2598 | 25 656 | 4.6 (2.6–8.1) | 2.9 (2.3–3.6) | 1.6 | 0.9–3.0 | 9.5 | 7.6 | 8 | 43 | |
The analyses were performed on all primary Sjögren's syndrome patients, and stratified by SSA and SSB autoantibody profile. Individuals with registered events before primary Sjögren's syndrome diagnosis date were excluded. Seventeen primary Sjögren's syndrome patients did not have available records on Ro/SSA and La/SSB antibodies, and are hence not included in subgroup analyses.
CI, confidence interval; SSA, Ro/SSA antibodies; SSB, La/SSB antibodies.
aIn subjects experiencing the event; bPrimary Sjögren's syndrome patients; cGeneral population comparators; dRo/SSA and La/SSB double‐positive; eRo/SSA and/or La/SSB single‐positive; fRo/SSA and La/SSB‐negative.